Ge Healthcare Drug Patent Portfolio

Ge Healthcare owns 3 orange book drugs protected by 8 US patents Given below is the list of Ge Healthcare's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8916131 Radiopharmaceutical composition 16 Sep, 2028
Active
US7270800 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition 03 Sep, 2025
Active
US8236282 Benzothiazole derivative compounds, compositions and uses 21 May, 2024 Expired
US7351401 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition 24 Jan, 2023 Expired
US8691185 Benzothiazole derivative compounds, compositions and uses 24 Jan, 2023 Expired
US6723303 Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane 20 Apr, 2021 Expired
US5560903 Method of enhancing paramagnetism in chelates for MRI 01 Oct, 2013 Expired
US5529766 Contrast agents 25 Jun, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Ge Healthcare.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 25 Jan, 2024 US8236282
Payment of Maintenance Fee, 8th Year, Large Entity 19 May, 2022 US8916131
Payment of Maintenance Fee, 8th Year, Large Entity 22 Sep, 2021 US8691185
Payment of Maintenance Fee, 8th Year, Large Entity 23 Jan, 2020 US8236282
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2019 US7351401
Payment of Maintenance Fee, 12th Year, Large Entity 07 Mar, 2019 US7270800
Post Issue Communication - Certificate of Correction 27 Nov, 2018 US7270800
Post Issue Communication - Certificate of Correction 14 Nov, 2018 US8236282
Post Issue Communication - Certificate of Correction 07 Nov, 2018 US8691185
Payment of Maintenance Fee, 4th Year, Large Entity 25 Jun, 2018 US8916131
Payment of Maintenance Fee, 4th Year, Large Entity 21 Sep, 2017 US8691185
Patent Term Extension Certificate 21 Mar, 2017 US7270800
Notice of Final Determination -Eligible 07 Dec, 2016 US7270800
FDA Final Eligibility Letter 29 Jul, 2016 US7270800
transaction for FDA Determination of Regulatory Review Period 15 Dec, 2015 US7270800


Ge Healthcare's Drug Patent Litigations

Ge Healthcare's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 28, 2000, against patent number US6723303. The petitioner , challenged the validity of this patent, with QUAY as the respondent. Click below to track the latest information on how companies are challenging Ge Healthcare's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6723303 March, 2000 Decision
(30 Oct, 2003)
QUAY


Ge Healthcare's Family Patents

Ge Healthcare drugs have patent protection in a total of 25 countries. It's US patent count contributes only to 22.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Ge Healthcare Drug List

Given below is the complete list of Ge Healthcare's drugs and the patents protecting them.


1. Omniscan

Omniscan is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5560903 Method of enhancing paramagnetism in chelates for MRI 01 Oct, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omniscan's drug page


2. Optison

Optison is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6723303 Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane 20 Apr, 2021
(3 years ago)
Expired
US5529766 Contrast agents 25 Jun, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Optison's drug page


3. Vizamyl

Vizamyl is protected by 5 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8916131 Radiopharmaceutical composition 16 Sep, 2028
(3 years from now)
Active
US7270800 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition 03 Sep, 2025
(10 months from now)
Active
US8236282 Benzothiazole derivative compounds, compositions and uses 21 May, 2024
(4 months ago)
Expired
US7351401 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition 24 Jan, 2023
(1 year, 8 months ago)
Expired
US8691185 Benzothiazole derivative compounds, compositions and uses 24 Jan, 2023
(1 year, 8 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vizamyl's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List